LEVULAN KERASTICK offers patients and health care practitioners a treatment option with a well-established safety and efficacy profile that can prevent the progression of actinic keratoses into skin ...
LEVULAN KERASTICK for topical solution, 20%, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is used to treat minimally to moderately thick actinic keratoses ...
A conference call will be held today, Wednesday, October 22, 5:00 p.m. E.D.T. DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announced today results from its Phase IIB clinical trial to compare the ...
Aminolevulinic acid HCl 20%; topical soln; contains alcohol. Following the application of Levulan Kerastick topical solution, photosensitization occurs through the metabolic conversion of ...
June 1, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for aminolevulinic acid HCl in combination with photodynamic therapy for the treatment of esophageal ...
We are confident that Sun Pharma will build upon the solid foundation our organization has established in the United States dermatology market to further expand access to Levulan® for patients with ...
Says FDA did not grant orphan status to Levulan therapy Levulan developed for prevention of skin cancer Co plans to close its SOTR clinical program Shares plunge 18 pct Aug 6 (Reuters) - DUSA ...
Acquiring the Canadian rights to LEVULAN KERASTICK (aminolevulinic acid hydrochloride) further expands the Sun Pharma Canada dermatology portfolio and reinforces the company's commitment to patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results